Phase II Study of Anti-GD2 3F8 Antibody and Biologic Response Modifiers for High-risk Neuroblastoma

Trial Profile

Phase II Study of Anti-GD2 3F8 Antibody and Biologic Response Modifiers for High-risk Neuroblastoma

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2013

At a glance

  • Drugs Beta glucan; Isotretinoin; Monoclonal antibody 3F8
  • Indications Neuroblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jun 2008 The expected completion date for this trial is now 1 Nov 2006, as reported by ClinicalTrials.gov
    • 25 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top